Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with disease modifying therapies

被引：0
|
作者：
Barone, S. [1 ]
Palmieri, C. [2 ]
Gallelli, L. [3 ]
Rania, V. [3 ]
Bruno, P. A. [1 ]
Pasquale, M. [1 ]
Pascarella, A. [1 ]
Manzo, L. [1 ]
De Sarro, G. [3 ]
Gambardella, A. [1 ]
Valentino, P. [1 ]
机构：
[1] Magna Graecia Univ Catanzaro, Inst Neurol, Dept Med & Surg Sci, Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Clin Biochem & Cell Biol, Biochem Lab, Dept Expt & Clin Med, Catanzaro, Italy
[3] Magna Graecia Univ Catanzaro, Clin Pharmacol Unit, Dept Hlth Sci, Sch Med, Catanzaro, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1091
引用
收藏
页码：866 / 866
页数：1
相关论文
共 50 条
  • [31] Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
    Capuano, Rocco
    Bisecco, Alvino
    Conte, Miriana
    Donnarumma, Giovanna
    Altieri, Manuela
    Grimaldi, Elena
    Franci, Gianluigi
    Chianese, Annalisa
    Galdiero, Massimiliano
    Coppola, Nicola
    Tedeschi, Gioacchino
    Gallo, Antonio
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [32] Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
    Czarnowska, Agata
    Tarasiuk, Joanna
    Zajkowska, Olga
    Wnuk, Marcin
    Marona, Monika
    Nowak, Klaudia
    Slowik, Agnieszka
    Jamroz-Wisniewska, Anna
    Rejdak, Konrad
    Lech, Beata
    Popiel, Malgorzata
    Rosciszewska-Zukowska, Iwona
    Perenc, Adam
    Bartosik-Psujek, Halina
    Swiderek-Matysiak, Mariola
    Siger, Malgorzata
    Ciach, Agnieszka
    Walczak, Agata
    Jurewicz, Anna
    Stasiolek, Mariusz
    Kania, Karolina
    Dyczkowska, Klara
    Kalinowska-Lyszczarz, Alicja
    Galus, Weronika
    Walawska-Hrycek, Anna
    Krzystanek, Ewa
    Chojdak-Lukasiewicz, Justyna
    Ubysz, Jakub
    Pokryszko-Dragan, Anna
    Kapica-Topczewska, Katarzyna
    Bazylewicz, Marcin
    Mironczuk, Anna
    Kulikowska, Joanna
    Kochanowicz, Jan
    Bialek, Marta
    Stolarz, Malgorzata
    Kubicka-Baczyk, Katarzyna
    Niedziela, Natalia
    Morawiec, Natalia
    Adamczyk-Sowa, Monika
    Podlecka-Pietowska, Aleksandra
    Nojszewska, Monika
    Zakrzewska-Pniewska, Beata
    Jasinska, Elzbieta
    Zaborski, Jacek
    Milewska-Jedrzejczak, Marta
    Zwiernik, Jacek
    Zwiernik, Beata
    Potemkowski, Andrzej
    Brola, Waldemar
    VACCINES, 2022, 10 (05)
  • [33] Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
    Ali, Ahya
    Dwyer, Deanna
    Wu, Qi
    Wang, Qin
    Dowling, Catherine A.
    Fox, David A.
    Khanna, Dinesh
    Poland, Gregory A.
    Mao-Draayer, Yang
    VACCINE, 2021, 39 (41) : 6111 - 6116
  • [34] Ocrelizumab attenuates the humoral response to SARS-CoV-2 compared with other disease modifying therapies in multiple sclerosis: a case-control study
    Conte, W.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 643 - 643
  • [35] T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapies
    Wolf, A. S.
    Ravussin, A.
    Konig, M.
    Overas, M. H.
    Solum, G.
    Kjonstad, I. F.
    Chopra, A.
    Holmoy, T.
    Harbo, H. F.
    Syversen, S. W.
    Jorgensen, K. K.
    Hogestol, E. A.
    Vaage, J. T.
    Celius, E. G.
    Lund-Johansen, F.
    Munthe, L. A.
    Nygaard, G. O.
    Mjaaland, S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 49 - 49
  • [36] Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
    Meschi, Silvia
    Matusali, Giulia
    Colavita, Francesca
    Lapa, Daniele
    Bordi, Licia
    Puro, Vincenzo
    Leoni, Bruno D.
    Galli, Claudio
    Capobianchi, Maria Rosaria
    Castilletti, Concetta
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (12) : 2010 - 2018
  • [37] Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 vaccine in a cohort of patients with multiple sclerosis
    Correa-Diaz, E. P.
    Barrera Madera, R.
    Torres Herran, G.
    Jacome Sanchez, C.
    Gualotuna Pachacama, W.
    Llerena Pallango, A.
    Piedra Andrade, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 838 - 838
  • [38] Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
    de la Maza, Susana Sainz
    Walo-Delgado, Paulette Esperanza
    Rodriguez-Dominguez, Mario
    Monreal, Enric
    Rodero-Romero, Alexander
    Chico-Garcia, Juan Luis
    Pariente, Roberto
    Rodriguez-Jorge, Fernando
    Ballester-Gonzalez, Ruben
    Villarrubia, Noelia
    Romero-Hernandez, Beatriz
    Masjuan, Jaime
    Costa-Frossard, Lucienne
    Villar, Luisa Maria
    VACCINES, 2023, 11 (04)
  • [39] Assessment of SARS-CoV-2 specific t-cell response in immunocompromised patients failing to seroconvert in response to sars-cov-2 vaccine
    Wiercinska, E.
    Jarisch, A.
    Daqiq-Mirdad, S.
    Hellstern, H.
    Ajib, S.
    Cremer, A.
    Nguyen, N. T. T.
    Dukat, A.
    Ullrich, E.
    Ciesek, S.
    Chow, K. -U.
    Serve, H.
    Seifried, E.
    Bader, P.
    Boenig, H.
    Bug, G.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 309 - 310
  • [40] B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
    Iannetta, Marco
    Landi, Doriana
    Cola, Gaia
    Campogiani, Laura
    Malagnino, Vincenzo
    Teti, Elisabetta
    Coppola, Luigi
    Di Lorenzo, Andrea
    Fraboni, Daniela
    Buccisano, Francesco
    Grelli, Sandro
    Mozzani, Marcello
    Zingaropoli, Maria Antonella
    Ciardi, Maria Rosa
    Nisini, Roberto
    Bernardini, Sergio
    Andreoni, Massimo
    Marfia, Girolama Alessandra
    Sarmati, Loredana
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345